SCHEMBL5136179

SCHEMBL5136179

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(C)Cc1ccc(C(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 3/20 0.46
C5AR1 P21730 1/20 0.46
TSHR P16473 3/20 0.42
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 2/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GLA P06280 1/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HSD11B1 P28845 2/20 0.37
NR1H3 Q13133 1/20 0.36
UCHL3 P15374 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649659 0.90 CASR (0.46) CASRC5AR1TSHRSMN1; SMN2ALDH1A1
SCHEMBL5135963 0.89 C5AR1 (0.48) C5AR1TSHRSMN1; SMN2LMNAMAPK1
SCHEMBL5136301 0.89 CASR (0.45) CASRC5AR1TSHRSMN1; SMN2ALDH1A1
SCHEMBL648044 0.88 CASR (0.44) CASRC5AR1TSHRALDH1A1KDM4E
SCHEMBL5138030 0.88 CASR (0.44) CASRC5AR1TSHRALDH1A1KDM4E
SCHEMBL5136921 0.87 C5AR1 (0.47) C5AR1TSHRSMN1; SMN2LMNAMAPK1
SCHEMBL5135854 0.85 C5AR1 (0.46) C5AR1TSHRSMN1; SMN2LMNAMAPK1
SCHEMBL5138038 0.85 C5AR1 (0.42) CASRC5AR1TSHRALDH1A1KDM4E
SCHEMBL5137931 0.84 GAA (0.47) CASRC5AR1TSHRSMN1; SMN2LMNA
SCHEMBL5135742 0.84 C5AR1 (0.40) CASRC5AR1TSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed